Article

Immune determinants of the association between tumor mutational burden and immunotherapy response across cancer types

2021-05-26

Abstract excerpt

The FDA has recently approved high tumor mutational burden (TMB), defined by ≥10 mutations/Mb, as a biomarker for the treatment of solid tumors with pembrolizumab, an immune checkpoint inhibitor (ICI) that targets PD1. However, recent studies testify that high TMB levels are only able to stratify ICI responders in a subset of cancer types, where the mechanisms underlying this observation have remained unknown. We...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 06c059c6-1433-5038-b990-11e3e578c037
DOI: 10.1101/2021.05.25.445197

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Immune determinants of the association between tumor mutational burden and immunotherapy response across cancer typesDOI 10.1101/2021.05.25.445197Read

Immune Determinants of the Association between Tumor Mutational Burden and Immunotherapy Response across Cancer Types.Semantic proximity Read

Correlate tumor mutation burden with immune signatures in human cancersSemantic proximity Read

A mutation-based gene set predicts survival benefit after immunotherapy across multiple cancers and reveals the immune response landscape.Semantic proximity Read

A Large-Scale Meta-Analysis Reveals Positive Feedback between Macrophages and T Cells That Sensitizes Tumors to Immunotherapy.Semantic proximity Read

PD-L1 expression and tumor mutational burden are independent biomarkers in most cancersSemantic proximity Read

Genomic landscape of the immunogenicity regulation in skin melanomas with diverse tumor mutation burden.Semantic proximity Read

The association between tumor mutational burden and prognosis is dependent on treatment context.Semantic proximity Read

High tumor mutational burden predicts survival and responses to ICI immunotherapy in a cancer-dependent mannerSemantic proximity Read

Integrated analysis of the immunological and genetic status in and across cancer types: impact of mutational signatures beyond tumor mutational burdenSemantic proximity Read

Comprehensive Analysis of the Relationships Between Tumor Mutation Burden With Immune Infiltrates in Cervical Cell CarcinomaSemantic proximity Read

TP53/BRAF mutation as an aid in predicting response to immune-checkpoint inhibitor across multiple cancer types.Semantic proximity Read

Genome and Transcriptome Biomarkers of Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors.Semantic proximity Read